Cobalamin insufficiency: Clinical manifestations and evidence-based therapeutic interventions

Vitamin B12 (cobalamin) is a water-soluble micronutrient exhibiting the most structurally complex configuration among all known vitamins, coordinated around a central cobalt ion. Within human physiology, cobalamin serves as an essential coenzyme for two vital metabolic enzymes: methionine synthase, which catalyzes the remethylation of homocysteine to methionine in conjunction with folate metabolism, and methylmalonyl-CoA mutase, which converts L-methylmalonyl-CoA into succinyl-CoA for energy production in the citric acid cycle. The optimal activity of these enzymatic pathways is crucial for de novo DNA and RNA synthesis, erythrocyte maturation in hematopoietic bone marrow, and the structural preservation of myelin sheaths surrounding peripheral and central nerve fibers.

Biologically active cobalamin is synthesized exclusively by bacteria and archaea, rendering animal-derived foods the primary natural dietary sources for humans. The highest concentrations are found in ruminant organ meats (beef and calf liver and kidneys), lean red meat, poultry, fatty marine fish (salmon, mackerel, herring), shellfish, eggs, and dairy products (fermented cheeses, yogurt, milk). Plant foods naturally lack active cobalamin; alleged plant sources, such as certain algae (e.g., spirulina), contain inactive corrinoid analogues (pseudovitamins) that lack human biological activity and may competitively inhibit true cobalamin absorption.

An adult human body maintains substantial endogenous cobalamin reserves ranging between 2 and 5 mg, stored predominantly in hepatocytes. Owing to minimal daily physiological losses and highly conservative enterohepatic recycling, these hepatic reserves can sustain physiological requirements for 3 to 5 years even in the total absence of intake. Nonetheless, cobalamin deficiency remains a prevalent clinical condition categorized into inadequate dietary consumption and secondary gastrointestinal malabsorption. Inadequate intake primarily affects individuals adhering to unsupplemented vegan or strict vegetarian diets, as well as malnourished geriatric populations.

In clinical practice, impaired gastrointestinal absorption constitutes the predominant mechanism of deficiency. Major etiologies include autoimmune metaplastic atrophic gastritis (Addison-Biermer pernicious anemia with circulating autoantibodies against gastric parietal cells or intrinsic factor), surgical bariatric or ileal resections, inflammatory bowel disease (Crohn's disease affecting the terminal ileum), celiac enteropathy, and Helicobacter pylori colonization. Furthermore, widespread chronic pharmacotherapy—specifically biguanides (metformin) and gastric acid suppressants such as proton pump inhibitors (PPIs) and H2-receptor antagonists—significantly impedes the dissociation and active absorption of dietary cobalamin.

Early clinical manifestations of cobalamin deficiency are characteristically subtle and insidious, presenting as persistent fatigue, muscular asthenia, generalized lethargy, cognitive dulling, and gastrointestinal complaints including anorexia, nausea, and glossodynia (Hunter's atrophic glossitis featuring a smooth, erythematous tongue surface). Within the hematopoietic system, impaired DNA replication in erythroid progenitors leads to megaloblastic anemia, marked by pronounced macrocytosis (elevated MCV), hypersegmented polymorphonuclear neutrophils, and potentially life-threatening pancytopenia in neglected cases.

Crucially, neuropsychiatric complications may develop independently of, or precede, overt hematological anomalies. Neurological sequelae arise from demyelination and axon loss, presenting as symmetrical peripheral paresthesias in a glove-and-stocking distribution, impaired vibratory sensation and proprioception, sensory ataxia, and spastic paraparesis characteristic of subacute combined degeneration of the spinal cord (SCD). Psychiatric presentations range from affective lability and severe depression to accelerated cognitive decline, memory impairment, and paranoid delirium.

The recommended dietary allowance (RDA) for cobalamin in healthy adults is established at 2.4 µg daily, increasing during pregnancy to 2.6 µg and throughout lactation to 2.8 µg per day. For adults over 50 years of age, age-associated gastric hypochlorhydria warrants regular intake of crystalline cobalamin from fortified foods or oral supplements. In strict vegan and vegetarian cohorts, routine prophylactic supplementation (daily oral regimens of 25–100 µg cyanocobalamin or 1000–2000 µg administered weekly) is clinically mandatory to maintain physiological serum concentrations and prevent subclinical tissue depletion.

Once clinically overt deficiency is confirmed, therapeutic repletion must be instituted without delay. Oral high-dose pharmacotherapy (1000 to 2000 µg cyanocobalamin daily) harnesses non-saturable passive transmucosal diffusion across the intestinal epithelium—bypassing the intrinsic factor pathway and absorbing roughly 1% of the administered dose. Nevertheless, in cases of severe malabsorption, total gastrectomy, active inflammatory bowel disorders, or prominent neurological compromise, initial parenteral replacement therapy remains the unequivocal clinical standard of care.

Parenteral cobalamin repletion via intramuscular (or deep subcutaneous) injection represents the definitive therapy of choice when intrinsic factor secretion is absent (Addison-Biermer pernicious anemia), following total or subtotal gastrectomy, and in patients presenting with acute neurological deficits requiring rapid tissue resaturation. A validated initial repletion protocol entails administering 1000 µg of hydroxocobalamin or cyanocobalamin intramuscularly daily or every other day for the first one to two weeks, transitioning to weekly administration until marked clinical and laboratory normalization is established.

Following hepatic reserve replenishment, patients with irreversible malabsorptive conditions transition to lifelong maintenance injections of 1000 µg administered every one to three months. During initial intensive therapy, clinical vigilance regarding serum potassium levels is warranted, as aggressive marrow erythroblast proliferation can precipitate transient hypokalemia. Serum methylmalonic acid (MMA) and total homocysteine levels serve as sensitive biomarkers to confirm metabolic restoration. Timely intramuscular intervention completely cures megaloblastic hematopoiesis and halts progressive, irreversible myelin destruction.